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Dear Sir, 
We were pleased to read the letter from Dr Puxeddu and co-workers, written in 
response to our observation that an increase pulmonary vessel volume, derived 
using quantitative CT analysis, strongly predicts mortality in patients with idiopathic 
pulmonary fibrosis (IPF).1 Dr Puxeddu and his team highlight a selection of studies 
that have identified pulmonary vascular alterations in IPF, similar to those seen in 
pulmonary venous occlusive disease (PVOD) and pulmonary capillary 
hemangiomatosis (PCH).2-4 They suggest that when considered in the light of these 
previous reports, our findings add support to the idea that vascular alterations might 
be the first pathological lesion in IPF preceding, and leading to, fibrogenesis.  
 
Linkage between fibrosis and alterations in pulmonary vessel density in IPF is not a 
new observation. The histopathological evaluation of surgical lung biopsy samples 
performed by Ebina et al established that tissue surrounding regions of fibrosis in IPF 
is characterised by an increase in vessel profusion, whilst the fibrotic tissue itself 
demonstrates a reduced number of vessels.2 In line with these findings, fibroblastic 
foci, a pathological hallmark of IPF,5 have been shown to be relatively avascular6 yet 
have a network of capillaries at the base of the lesion. Furthermore, within fibrotic 
regions of histopathological IPF samples, the normal reduction in vessel profusion 
with increasing distance from the alveoli spaces has been shown to be disrupted.7  
 
More recently, in vivo studies in animal models have highlighted the varied effects 
on pulmonary fibrosis mediated by modifying angiogenic pathways. In a rat model of 
bleomycin-induced pulmonary fibrosis, vascular endothelial growth factor (VEGF), an 
angiogenic mediator, was shown to reduce the severity of pulmonary hypertension 
yet concomitantly increase the severity of pulmonary fibrosis.8 In a similar mouse 
model, an angiostatic chemokine CXCL11, was found to reduce total lung collagen 
deposition and overall fibrosis extent on morphometric analysis. However, the 
reduction in fibrosis rather than being mediated through effects on pulmonary 
fibroblasts, was linked to reductions in numbers of pulmonary endothelial cells and 
the inhibition of angiogenesis.9 Building on these reports, endostatin, a collagen 
degradation product that inhibits the VEGF receptor, has been shown to ameliorate 
bleomycin-induced pulmonary fibrosis possibly by reducing aberrant pulmonary 
angiogenesis and reducing alveolar epithelial cell apoptosis.10 
 
Despite the apparent corroboration from these various in vivo models, the 
translation of animal models of pulmonary fibrosis and vascular proliferation to 
human IPF studies must be guarded. Similarly, extrapolating relationships between 
the pulmonary microvasculature and fibrosis at a cellular level to the more 
macroscopic changes identified using quantitative CT analysis is a large, and possibly 
unwarranted, step.  Nevertheless, dynamic or functional imaging studies may further 
elucidate the complex interactions that exist between the vessels in the lung and the 
development of fibrosis.  
 
With regard to the specific suggestion that vascular stresses occurring secondary to 
either PVOD or PCH may be the first pathological lesion in the IPF lung” as Dr 
Puxeddu et al. states, it is worth pointing out that fibrous intimal narrowing of 
vessels is frequently seen on a histopathological analysis of pulmonary fibrosis, and 
thus adjacent vascular changes could be secondary to, or an epiphenomenon of, the 
fibrosing process itself. Thus it remains unclear whether vascular proliferation 
represents a compensatory response to subjacent pulmonary fibrosis, contributes to 
fibrogenesis, or represents a combination of the two.  
 
Despite our intentional restraint in suggesting hypotheses to explain our 
observations about pulmonary vascular volume in IPF, the interest our work has 
generated is encouraging. Whilst exact relationships are elusive, it is becoming 
increasingly apparent that understanding the complexities of the pulmonary 
vasculature is an important but neglected field of study in IPF. 
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